TP53 mutations, which are among the most common genetic alterations in lung cancer, can promote resistance to chemotherapy agents and may also alter the tumour’s immune environment, reducing the effectiveness of immune checkpoint inhibitors. This evidence concerns the gene TP53 and lung carcinoma.